Adaptive Biotechnologies Corporation (NASDAQ:ADPT) finished Wednesday with an addition of $0.17 to close at $6.50, an upside of 2.69 percent. An average of 1,454,500 shares of common stock have been traded in the last five days. There was a gain of $0.28 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 1,326,970 shares traded, while the 50-day average volume stands at 1,187,598.
ADPT stock has decreased by -17.20% in the last month. The company shares reached their 1-month lowest point of $5.99 on 08/18/23. With the stock rallying to its 52-week high on 01/18/23, shares of the company touched a low of $5.96 and a high of $11.31 in 52 weeks. It has reached a new high 10 times so far this year and lost -14.92% or -$1.14 in price. In spite of this, the price is down -42.53% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
ADPT stock investors should be aware that Adaptive Biotechnologies Corporation (ADPT) stock had its last reported insider trading activity 16 days ago on Aug 08. In this transaction, the insider spent $68,997. Chief Commercial Officer, MRD, SOOD NITIN, disposed of 5,652 shares at a price of $6.78 on Aug 07. The insider now owns more than $38,321 worth of shares. Prior to that, Chief Financial Officer PETERSON TYCHO went on to Sale 134,961 shares at $8.14 each on Jun 20. An amount of $1,098,583 was transacted.
Valuation Metrics
Adaptive Biotechnologies Corporation (ADPT) stock’s beta is 1.24. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 4.88, the price-to-book (PB) ratio at 2.37.
Financial Health
The quick ratio of Adaptive Biotechnologies Corporation for the three months ended June 29 was 4.80, and the current ratio was 5.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.32 and a total debt to equity ratio of 0.32 for the quarter ending June 29. Adaptive Biotechnologies Corporation’s EBITDA margin for the year ending June 29 is -91.75%. Its gross profit as reported stood at $127.4 million compared to revenue of $185.31 million.
Earnings Surprise
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$47.81 million in the quarter, while revenues of -$57.7 million were shrunk -8.87%. The analyst consensus anticipated Adaptive Biotechnologies Corporation’s latest quarter earnings to come in at -$0.35 per share, but it turned out to be -$0.33, a 5.70% surprise. For the quarter, EBITDA amounted to -$44.08 million. Shareholders own equity worth $144.65 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Adaptive Biotechnologies Corporation (ADPT) price momentum. RSI 9-day as of the close on 23 August was 45.07%, suggesting the stock is Neutral, with historical volatility in this time frame at 33.75%.
As of today, ADPT’s price is $6.32 +4.50% or $0.28 from its 5-day moving average. ADPT is currently trading -19.35% lower than its 20-day SMA and -22.80% lower than its 100-day SMA. However, the stock’s current price level is -18.14% below the SMA50 and -16.45% below the SMA200.
The stochastic %K and %D were 27.77% and 18.82%, respectively, and the average true range (ATR) was 0.35. With the 14-day stochastic at 42.48% and the average true range at 0.37, the RSI (14) stands at 43.39%. The stock has reached 0.13 on the 9-day MACD Oscillator while the 14-day reading was at 0.01.
